参考文献/References:
[1] Roth GA,Mensah GA,Johnson CO,et al. Global burden of cardiovascular diseases and risk factors,1990-2019:update from the GBD 2019 Study[J]. J Am Coll Cardiol,2020,76(25):2982-3021.
[2] Hoogeveen RC,Ballantyne CM. Residual cardiovascular risk at low LDL:remnants,lipoprotein(a),and inflammation[J].?Clin Chem,2021,67(1):143-153.
[3] Huynh K. Targeting Lp(a) to reduce ASCVD risk[J]. Nat Rev Cardiol,2020,17(10):612.
[4] Grundy SM,Stone NJ,Bailey AL,et al. 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Managementof Blood Choles-terol:A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines[J]. ?J Am Coll Cardiol,2019,73(24):e285-e350.
[5] Mach F,Baigent C,Catapano AL,et al. 2019 ESC/EAS Guidelines for themanagement of dyslipidaemias:lipid modification to reduce cardiovascular risk[J]. Eur Heart J,2020,41(1):111-188.
[6] Cegla J,Neely RDG,France M,et al. HEART UK consensus statement on Lipoprotein(a):a call to action[J]. Atherosclerosis,2019,291:62-70.
[7] Tsimikas S.?A test in context:lipoprotein(a): diagnosis,prognosis,controv-ersies,and emerging therapies[J]. J Am Coll Cardiol,2017,69(6):692-711.
[8] Utermann G,Menzel HJ,Kraft HG,et al. Lp(a) glycoprotein phenotypes. Inheritance and relation to Lp(a)-lipoprotein concentrations in plasma[J]. J Clin Invest,1987,80(2):458-465.
[9] Lackner C,Boerwinkle E,Leffert CC,et al. Molecular basis of apolipoprotein (a) isoform size heterogeneity as revealed by pulsed-field gel electrophoresis[J]. J Clin Invest,1991,87(6):2153-2161.
[10] Schmidt K,Noureen A,Kronenberg F,et al. Structure,function,and genetics of lipoprotein (a)[J]. J Lipid Res,2016,57(8):1339-1359.
[11] Kronenberg F. Human genetics and the causal role of lipoprotein(a) for various diseases[J]. Cardiovasc Drugs Ther,2016,30(1):87-100.
[12] Wang Z,Zhai X,Xue M,et al. Prognostic value of lipoprotein(a) level in patients with coronary artery disease:a meta-analysis[J]. Lipids Health Dis,2019,18(1):150.
[13] Gudbjartsson DF,Thorgeirsson G,Sulem P,et al. Lipoprotein(a) concentration and risks of cardiovascular disease and diabetes[J]. J Am Coll Cardiol,2019,74(24):2982-2994.
[14] Langsted A,Nordestgaard BG,Kamstrup PR.? Elevated lipoprotein(a) and risk of ischemic stroke[J]. ?J Am Coll Cardiol,2019,74(1):54-66.
[15] Fu H,Zhang D,Zhu R,et al. Association between lipoprotein(a) concentration and the risk of stroke in the Chinese Han population: a retrospective case-control study[J]. Ann Transl Med,2020,8(5):212.
[16] Kubota Y,Folsom AR,Ballantyne CM,et al. Lipoprotein(a) and abdominal aortic aneurysm risk:The Atherosclerosis Risk in Communities study[J]. Atherosclerosis,2018,268:63-67.
[17] Schwartz GG,Steg PG,Szarek M,et al. Peripheral artery disease and venous thromboembolic events after acute coronary syndrome:role of lipoprotein(a) and modification by alirocumab: prespecified analysis of the ODYSSEY OUTCOMES randomized clinical trial[J]. Circulation,2020,141(20):1608-1617.
[18] Wilson DP,Jacobson TA,Jones PH,et al. Use of lipoprotein(a) in clinical practice:a biomarker whose time has come. A scientific statement from the national lipid association[J]. J Clin Lipidol,2019,13(3):374-392.
[19] Argraves KM,Kozarsky KF,Fallon JT,et al. The atherogenic lipoprotein Lp(a) is internalized and degraded in a process mediated by the VLDL receptor[J]. J Clin Invest,1997,100(9):2170-2181.
[20] Schnitzler JG,Hoogeveen RM,Ali L,et al. Atherogenic lipoprotein(a) increases vascular glycolysis,thereby facilitating inflammation and leukocyte extravasation[J]. Circ Res,2020,126(10):1346-1359.
[21] Feric NT,Boffa MB,Johnston SM,et al. Apolipoprotein(a) inhibits the conversion of Glu-plasminogen to Lys-plasminogen: a novel mechanism for lipoprotein(a)-mediated inhibition of plasminogen activation[J]. ?J Thromb Haemost,2008,6(12):2113-2120.
[22] Rhainds D,Brodeur MR,Tardif JC. Lipoprotein(a):when to measure and how to treat?[J]. Curr Atheroscler Rep,2021,23(9):51.
[23] Burgess S,Ference BA,Staley JR,et al. Association of LPA variants with risk of coronary disease and the implications for lipoprotein(a)-lowering therapies:a Mendelian randomization analysis[J]. ?JAMA Cardiol,2018,3(7):619-627.
[24] Bittner VA,Szarek M,Aylward PE,et al. Effect of alirocumab on lipoprotein(a) and cardiovascular risk after acute coronary syndrome[J]. J Am Coll Cardiol,2020,75(2):133-144.
[25] Parish S,Hopewell JC,Hill MR,et al. Impact of apolipoprotein(a) isoform size on lipoprotein(a) lowering in the HPS2-THRIVE Study[J]. Circ Genom Precis Med,2018,11(2):e001696.
[26] Roeseler E,Julius U,Heigl F,et al. Lipoprotein apheresis for lipoprotein(a)-associated cardiovascular disease: prospective 5 years of follow-up and apolipoprotein(a) characterization[J]. Arterioscler Thromb Vasc Biol,2016,36(9):2019-2027.
[27] Cao YX,Liu HH,Li S,et al. A meta-analysis of the effect of PCSK9-monoclonal antibodies on circulating lipoprotein (a) levels[J].?Am J Cardiovasc Drugs,2019,19(1):87-97.
[28] Ray KK,Stoekenbroek RM,Kallend D,et al. Effect of an siRNA therapeutic targeting PCSK9 on atherogenic lipoproteins:prespecified secondary end points in ORION 1[J]. Circulation,2018,138(13):1304-1316.
[29] Ridker PM,Rane M. Interleukin-6 signaling and anti-interleukin-6 therapeutics in cardiovascular disease[J]. Circ Res,2021,128(11):1728-1746.
[30] Ridker PM,Devalaraja M,Baeres FMM,et al. IL-6 inhibition with ziltivekimab in patients at highatherosclerotic risk (RESCUE):a double-blind,randomised,placebo-controlled,phase 2 trial[J]. Lancet,2021,397(10289):2060-2069.
[31] Pe?in I,Reiner ?.? Novel experimental agents for the treatment of hypercholesterolemia[J]. J Exp Pharmacol,2021,13:91-100.
[32] Tsimikas S,Karwatowska-Prokopczuk E,Gouni-Berthold I,et al. Lipoprotein(a) reduction in persons with cardiovascular disease[J]. N Engl J Med,2020,382(3):244-255.
相似文献/References:
[1]汤月霞 吴宗贵.脂蛋白a用于预测心血管疾病的争议[J].心血管病学进展,2019,(8):1158.[doi:10.16806/j.cnki.issn.1004-3934.2020.08.022]
TANG Yuexia,WU Zonggui.Controversies about the Use of Lipoprotein() in Predicting Cardiovascular Disease[J].Advances in Cardiovascular Diseases,2019,(8):1158.[doi:10.16806/j.cnki.issn.1004-3934.2020.08.022]
[2]史云聪 郭艺芳.2型糖尿病和动脉粥样硬化性心血管疾病的关系[J].心血管病学进展,2020,(5):485.[doi:10.16806/j.cnki.issn.1004-3934.2020.05.011]
SHI Yuncong,GUO Yifang.Relationship Between Type 2 Diabetes Mellitus and Atherosclerotic Cardiovascular Disease[J].Advances in Cardiovascular Diseases,2020,(8):485.[doi:10.16806/j.cnki.issn.1004-3934.2020.05.011]
[3]李艳茹,白世茹,李如意,等.PCSK9抑制剂在血脂代谢中的研究进展[J].心血管病学进展,2020,(7):729.[doi:10.16806/j.cnki.issn.1004-3934.2020.07.014]
LI Yanru,BAI Shiru,LI Ruyi,et al.PCSK9 Inhibitors in Lipid Metabolism[J].Advances in Cardiovascular Diseases,2020,(8):729.[doi:10.16806/j.cnki.issn.1004-3934.2020.07.014]
[4]马晓磊 朱国斌.Wnt信号与动脉粥样硬化性心血管疾病研究进展[J].心血管病学进展,2020,(8):855.[doi:10.16806/j.cnki.issn.1004-3934.2020.08.018]
MA Xiaolei,ZHU Guobin.Wnt Signaling and Atherosclerotic Cardiovascular Disease[J].Advances in Cardiovascular Diseases,2020,(8):855.[doi:10.16806/j.cnki.issn.1004-3934.2020.08.018]
[5]黄毕.慢性肾脏病合并动脉粥样硬化性心血管疾病的调脂治疗进展[J].心血管病学进展,2020,(10):1065.[doi:10.16806/j.cnki.issn.1004-3934.2020.10.016]
HUANG Bi.Lipid Management in Patients with Chronic Kidney Disease and Arteriosclerotic Cardiovascular Disease[J].Advances in Cardiovascular Diseases,2020,(8):1065.[doi:10.16806/j.cnki.issn.1004-3934.2020.10.016]
[6]姚雅洁 蔡恒.PCSK9抑制剂Evolocumab动脉粥样硬化性心血管疾病的研究进展[J].心血管病学进展,2020,(12):1285.[doi:10.16806/j.cnki.issn.1004-3934.2020.12.015]
YAO Yajie,CAI Heng.PCSK9 Inhibitor Evolocumab and ASCVD[J].Advances in Cardiovascular Diseases,2020,(8):1285.[doi:10.16806/j.cnki.issn.1004-3934.2020.12.015]
[7]林琳 李京秀 闫娜 刘丹阳 查理 金恩泽.脂蛋白a的治疗现状及研究新方向[J].心血管病学进展,2021,(6):543.[doi:10.16806/j.cnki.issn.1004-3934.2021.06.016]
LIN Lin,LI Jingxiu,YAN Na,et al.The Therapeutic Status and Research Prospects of the Treatment of Lipoprotein a[J].Advances in Cardiovascular Diseases,2021,(8):543.[doi:10.16806/j.cnki.issn.1004-3934.2021.06.016]
[8]曹岩 颜培实.残余胆固醇与动脉粥样硬化性心血管疾病[J].心血管病学进展,2021,(10):920.[doi:10.16806/j.cnki.issn.1004-3934.2021.10.014]
CAO Yan,YAN Peishi.Remnant Cholesterol And Atherosclerotic?ardiovascular Disease[J].Advances in Cardiovascular Diseases,2021,(8):920.[doi:10.16806/j.cnki.issn.1004-3934.2021.10.014]
[9]蔡薇 杨堰焯 刘昊凌.甘油三酯葡萄糖乘积指数与糖尿病血管病变的研究进展[J].心血管病学进展,2022,(3):245.[doi:10.16806/j.cnki.issn.1004-3934.2022.03.000]
CAI Wei,YANG Yanzhuo,LIU Haoling.Triglyceride-Glucose Index and Diabetic Vascular Disease[J].Advances in Cardiovascular Diseases,2022,(8):245.[doi:10.16806/j.cnki.issn.1004-3934.2022.03.000]
[10]陈林滔 田清平 刘梅林.残余胆固醇预测动脉粥样硬化性心血管疾病的研究进展[J].心血管病学进展,2022,(6):492.[doi:10.16806/j.cnki.issn.1004-3934.2022.06.004]
CHEN Lintao,TIAN Qingping,LIU Meilin.Remnant Cholesterol in Predicting Atherosclerotic Cardiovascular Diseases[J].Advances in Cardiovascular Diseases,2022,(8):492.[doi:10.16806/j.cnki.issn.1004-3934.2022.06.004]